Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregularheartbeats that can be life threatening. Your healthcare provider should do tests before you start taking BRAFTOVI

with binimetinib and during your treatment to check your body salts (electrolytes). Tell your healthcare provider rightaway if you feel faint, lightheaded, dizzy or if you feel your heart beating irregularly or fast while taking BRAFTOVI

with binimetinib. These symptoms may be related to QT prolongation.

The most common side effects of BRAFTOVI when taken with binimetinib, include:

 fatigue

 nausea

 vomiting

 abdominal pain

 pain or swelling of your joints

BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of BRAFTOVI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Array BioPharma Inc. at 1-844-792-7729.

How should I store BRAFTOVI?

 Store BRAFTOVI at room temperature between 68°F to 77°F (20°C to 25°C).

 Store BRAFTOVI in the original bottle.

 Keep the BRAFTOVI bottle tightly closed and protect it from moisture.

 BRAFTOVI comes with a desiccant packet in the bottle to help protect your medicine from moisture. Do not remove the

desiccant packet from the bottle.

Keep BRAFTOVI and all medicines out of the reach of children. 

 

General information about the safe and effective use of BRAFTOVI.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BRAFTOVIfor a condition for which it was not prescribed. Do not give BRAFTOVI to other people, even if they have the same

symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information aboutBRAFTOVI that is written for health professionals.

What are the ingredients in BRAFTOVI?

Active ingredient: encorafenib

Inactive ingredients: copovidone, poloxamer 188, microcrystalline cellulose, succinic acid, crospovidone, colloidal silicondioxide, and magnesium stearate of vegetable origin

Capsule shell: gelatin, titanium dioxide, iron oxide red, iron oxide yellow, ferrosoferric oxide, monogramming ink(pharmaceutical glaze, ferrosoferric oxide, propylene glycol)

Distributed by: Array BioPharma Inc. Boulder, Colorado 80301.

For more information, go to www.BRAFTOVIMEKTOVI.com or call 1-844-792-7729.

© 2018 Array BioPharma Inc. All rights reserved.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: June 2018